ORAL pre-exposure prophylaxis or PrEP are medications that are highly effective at reducing the risk of HIV transmission, but they don't work for everyone.
HIV has been around for more than 40 years, yet it remains a major public health problem.
While HIV is commonly thought of as an infection that predominantly affects men who have sex with men, 53 percent of people living with HIV in 2022 were women and girls.
And of the 1.3 million new HIV infections that year, 46 percent were among adolescent girls and women, the majority living in sub-Saharan Africa.
Driving down new HIV infections is a key part of achieving a 90 percent reduction in HIV infections by 2030, as called for in the Sustainable Development Goals.
But it will require access to a variety of prevention methods to ensure all those at risk of contracting HIV can choose methods that best suit their circumstances.
Eliminating HIV transmission currently relies on using antiretroviral drugs in two different ways.
The first is 'treatment as prevention', whereby the viral load in someone living with HIV is suppressed to undetectable levels.
This strategy underpins UNAIDS 90-90-90 campaign to test 90 percent of individuals, ensure that 90 percent of these individuals are on treatment, and that 90 percent of these individuals are fully suppressed to decrease transmission of HIV.
A study published earlier this year in The Lancet confirmed that if someone's viral load is less than 1,000 copies of the HIV virus per millilitre of bodily fluids, the risk of HIV transmission through sex is virtually zero. This finding supports the Undetectable = Untransmittable (U=U) global campaign.
The second strategy is HIV pre-exposure prophylaxis, or PrEP, in which antiretroviral drugs are used to protect individuals at high risk of acquiring HIV through sex from their partners.
First generation HIV PrEP was approved in 2012. An oral pill called Truvada combines two antiretroviral drugs, tenofovir disoproxil and emtricitabine, which target reverse transcriptase, a key HIV protein the virus needs to reproduce.
Oral PrEP works, as long as those using it remember to take it.
Men can miss some doses of PrEP and still be protected from HIV, but oral PrEP is less forgiving if a woman misses taking her daily pill.
Daily pills are needed to maintain protective drug levels in the vagina, which is the main route of HIV acquisition in women. In contrast, higher drug levels are reached in the rectum, which is the main route of HIV entry in men who have sex with men.
Context is important is understanding why women don't just take their daily oral PrEP.
Oral PrEP use in adolescent girls and young women in sub-Saharan Africa is associated with stigma due to lack of pill storage options, which makes discrete use of the medication difficult, and side effects.
In addition, daily oral regimens are challenging for adolescent girls and young women to stick to. While adherence might be high at the start of taking oral PrEP, it decreases over time.
Having the ability to choose from and access a variety of PrEP methods allows women to choose what suits their different contexts and what is suitable at different points of their reproductive lifespans.
Women may prefer PrEP that is delivered in a different way — for example, via injection or implant, or vaginally — as well as medication that is longer-acting and requires less frequent dosing — for example, once every two months or less often, as opposed to daily.
Choice and diversity of options resulting in an increase in adherence and uptake is well established for contraceptives to prevent unplanned pregnancies. The same options could be provided for women to protect themselves against acquiring HIV.
Second-generation PrEP options include the long-acting injectable cabotegravir. Cabotegravir belongs to the class of HIV drugs called integrase inhibitors. It is delivered into the body by intramuscular injections once every eight weeks for protection against HIV.
A phase three randomised clinical trial performed in seven countries in sub-Saharan Africa showed that the efficacy of injectable cabotegravir was greater when compared to daily oral Truvada for preventing HIV in uninfected cisgender women. Only four women became infected in the cabotegravir group, compared with 36 in the Truvada group.
While oral and injectable PrEP medications are effective, not all women want to take systemic forms of PrEP, because of fear of side effects. These women may prefer a topical form of PrEP, for example direct delivery of the antiretroviral drug into the vagina.
Vaginal delivery of drugs is an untapped frontier for drug discovery.
For topical PrEP, this has the advantage of delivering high antiretroviral drug levels locally in the vagina, with minimal drug levels in a woman's system, minimal side effects and a reduced chance of the virus becoming resistant to the drug.
Vaginal delivery can come in a variety of forms, including gels, tablets, films and intravaginal rings.
However, the only form of topical PrEP that has so far shown efficacy in preventing HIV infection in phase three clinical studies is the dapivirine ring.
The dapivirine ring is the only PrEP strategy specifically designed for women. It is an intravaginal ring made of flexible silicone loaded with 25mg of the antiretroviral drug, dapivirine, which is gradually released into the vagina over a four-week period.
Phase three studies showed the dapivirine ring could reduce HIV acquisition by 30 percent compared to a placebo ring, with efficacy being lower in women younger than 21 years of age due to low adherence.
However, follow-up studies with the dapivirine ring showed that it could provide about 50 percent or more protection if used consistently.
The ring received WHO prequalification in 2020 and has regulatory approvals in a limited number of countries, including Kenya, Rwanda, South Africa, Uganda and Zimbabwe.
There are also devices in the development stage that go one step further, called multipurpose prevention technologies.
These include intravaginal rings designed to not only prevent HIV but also prevent unplanned pregnancy and even treat bacterial vaginosis.
Bacterial vaginosis commonly occurs when the bacteria living in a woman's vagina are out of balance.
The condition results in vaginal inflammation and increases the risk of a woman acquiring HIV and other STIs, as well as increasing the risk of other adverse sexual and reproductive health outcomes.
In contrast, women who have an optimal vaginal microbiome, dominated by beneficial bacteria, are protected against HIV.
A product delivering molecules to the vagina that can target or prevent bacterial vaginosis as well as prevent HIV may also increase the efficacy of topical PrEP.
One device addressing multiple targets has the advantage of potentially addressing stigma associated with an agent specifically being used to prevent HIV, in addition to improving compliance and ultimately effectiveness.
Women having choice and access to diverse biomedical HIV prevention strategies and input into the design of these interventions will be important for achieving the goal of eliminating HIV transmission by 2030.
Professor Gilda Tachedjian is a Senior Principal Research Fellow at the Burnet Institute and Adjunct Professor at Monash University. Her research focuses on antivirals for HIV treatment and prevention, with a particular focus on HIV prevention in women and understanding the role of the vaginal microbiome in modulating HIV acquisition. Her ultimate goal is to translate her discoveries into novel interventions to optimise the vaginal microbiome to transform women's sexual and reproductive health
360info
Fri Dec 01 2023
An intravaginal ring made from silicone and loaded with antiretroviral drug dapivirine may help women reduce their risk of getting HIV. - Flickr/NIAID/via 360info
Bomba selamatkan tiga subkontrakor terkandas di kren pengangkat
Ketiga-tiga mangsa lelaki itu masing-masing berusia 24, 26 dan 32 tahun terkandas dengan anggaran ketinggian dua tingkat.
Hulu Perak daerah terbaharu dilanda banjir kilat
Banjir kilat berlaku disebabkan hujan lebat berterusan selama dua jam di sekitar Gerik.
Kejayaan pembangunan Sabah jadi kayu ukur pada PRN, PRU16 - Rafizi
Rafizi berkata kerjasama antara parti adalah perkara yang terus dibincangkan dalam kerangka semangat Kerajaan Perpaduan.
88 badan pensijilan halal luar negara dapat pengiktirafan JAKIM
Jabatan Kemajuan Islam Malaysia (JAKIM) telah memberikan pengiktirafan kepada 88 badan pensijilan halal luar negara setakat Mei tahun ini.
eWarga Emas bentuk sistem penyampaian perkhidmatan berkesan, bersepadu - Noraini
Portal sistem warga emas (eWarga Emas) dibangunkan bagi membentuk sistem penyampaian perkhidmatan warga emas yang berkesan dan bersepadu.
MITRA lulus lebih RM95 juta untuk 11 program masyarakat India
Kesemua program yang dalam pelaksanaan itu memberi tumpuan kepada usaha memperkasakan sosioekonomi komuniti India dalam negara.
Kestabilan sosiopolitik Sabah bolehkan agihan ekonomi saksama - Juhar
Smber daya, kekayaan alam semula jadi dan potensi ekonomi dalam masyarakat dapat dibahagi dengan cara memberi peluang sama kepada rakyat.
Kenanga jangka OPR stabil 3.0 peratus pada 2025
Kenanga Investment Bank Bhd menjangka Kadar Dasar Semalaman (OPR) kekal stabil pada 3.0 peratus sepanjang 2025.
Johor sasar jumlah ternakan cecah 200,000 ekor pada 2027
Johor menyasarkan jumlah ternakan di negeri ini mencapai hingga 200,000 ekor pada 2027 setelah berjaya mencapai jumlah pengeluaran ternakan sebanyak 152,000 ekor hingga bulan lepas.
Hargai warga emas melalui penjagaan, hormat dan penglibatan - Lee Lam Thye
Lee Lam Thye menekankan keperluan mendesak untuk menghargai warga emas melalui penjagaan, hormat, dan penglibatan yang lebih baik.
Rawatan PrEP perlu dilihat dengan lebih meluas
Apa yang penting adalah bidang perubatan bertujuan merawat sesiapa sahaja dan bukannya menghukum.